QR رمز

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)

<i>Clostridioides</i> <i>difficile</i> infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of r...

وصف كامل

محفوظ في:
المؤلفون الرئيسيون: Sahil Khanna, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa von Moltke, Mark H. Wilcox
التنسيق: Artigo
اللغة:Inglês
منشور في: MDPI AG 2022-09-01
سلاسل:Antibiotics
الموضوعات:
<i>Clostridioides</i> <i>difficile</i> infection (CDI)
SER-109
microbiome therapeutics
Firmicutes
microbial diversity
recurrent CDI
الوصول للمادة أونلاين:https://www.mdpi.com/2079-6382/11/9/1234
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة